Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits
暂无分享,去创建一个
T. Lecompte | A. Godier | O. Collignon | F. Plénat | J. Carteaux | Marion Durand | G. Corbonnois | M. Hacquard | Véronique Notet
[1] U. Hedner. Recombinant activated factor VII as a universal haemostatic agent. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[2] R. Martineau,et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.
[3] Dougald M Monroe,et al. The use of recombinant factor VIIa in the treatment of bleeding disorders. , 2004, Blood.
[4] E. Kirkman,et al. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig. , 2007, The Journal of trauma.
[5] J. Vincent,et al. Management of bleeding following major trauma: an updated European guideline , 2010, Critical care.
[6] Kevin Fox,et al. Experience-dependent plasticity mechanisms for neural rehabilitation in somatosensory cortex , 2009, Philosophical Transactions of the Royal Society B: Biological Sciences.
[7] G. Gallioli,et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. , 1998, Intensive care medicine.
[8] C. Samama,et al. Modified Folts models in the rabbit: variations on a well worn theme. , 2009, European journal of anaesthesiology.
[9] S. Bélisle,et al. Efficacy and safety of recombinant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. , 2008, The Annals of thoracic surgery.
[10] R. Rossaint,et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. , 2005, The Journal of trauma.
[11] I. C. Tudor,et al. The risk associated with aprotinin in cardiac surgery. , 2006, The New England journal of medicine.
[12] G. Gallioli,et al. Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study , 1998, Intensive Care Medicine.
[13] J. Holcomb,et al. RECOMBINANT FACTOR VIIA REDUCES REBLEED HEMORRHAGE VOLUME IN A SWINE AORTOTOMY MODEL: A RANDOMIZED DOUBLE-BLINDED STUDY , 2007, Shock.
[14] J. Stamler,et al. Intravenous Nitroglycerin Infusion Inhibits Cyclic Blood Flow Responses Caused by Periodic Platelet Thrombus Formation in Stenosed Canine Coronary Arteries , 1991, Circulation.
[15] Rolf Rossaint,et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective , 2006, Critical care.
[16] S. Stanworth,et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. , 2007, The Cochrane database of systematic reviews.
[17] S. Rapaport,et al. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. , 1990, Blood.
[18] J. Holcomb,et al. Preclinical trauma studies of recombinant factor VIIa , 2005, Critical care.
[19] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[20] J. Folts. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. , 1991, Circulation.
[21] M. Chiariello,et al. Induction of Tissue Factor in the Arterial Wall During Recurrent Thrombus Formation , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[22] E. Erhardtsen,et al. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects , 2005, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[23] F. Sellke,et al. Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery , 2009, Circulation.
[24] A. Pusateri,et al. Effect of haemodilution, acidosis, and hypothermia on the activity of recombinant factor VIIa (NovoSeven®) , 2008, British journal of anaesthesia.